How many drugs treat Muscle relaxation, function?

Drug Landscape tracks 10 marketed treatments for Muscle relaxation, function (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/muscle-relaxation-function.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Muscle relaxation, function — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Muscle relaxation, function (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Muscle relaxation, function, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Nimbex	CISATRACURIUM	AbbVie	Nondepolarizing Neuromuscular Blocker	Acetylcholine receptor	1995-01-01
Nimbex	Cisatracurium Besylate	AbbVie	Nondepolarizing Neuromuscular Blocker	Acetylcholine receptor	1995-01-01
Zemuron	ROCURONIUM	Fresenius Kabi	Nondepolarizing Neuromuscular Blocker	Acetylcholine receptor	1994-01-01
Rocuronium	Rocuronium Bromide	Merck & Co.	Nondepolarizing neuromuscular blocking agent	Cholinergic receptors at the motor end-plate	1994-01-01
Mivacron	MIVACURIUM	AbbVie	Nondepolarizing Neuromuscular Blocker	Acetylcholine receptor	1992-01-01
Atracurium	Atracurium Besylate	Pfizer	Nondepolarizing skeletal muscle relaxant	Cholinergic receptor sites on motor end-plate	1983-01-01
Succinylcholine Chloride	SUXAMETHONIUM	Novartis	Depolarizing Neuromuscular Blocker	Muscle-type nicotinic acetylcholine receptor	1952-01-01
Dextrotubocurarine Chloride	TUBOCURARINE	Bristol-Myers Squibb	tubocurarine	Acetylcholine receptor	1945-01-01
Metocurine	dimethyltubocurarinium	Eli Lilly	metocurine	Acetylcholine receptor
Succinylcholine	Succinylcholine	Charles University, Czech Republic		Muscle-type nicotinic acetylcholine receptor, Acetylcholinesterase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Muscle relaxation, function
AbbVie · 3 drugs in Muscle relaxation, function
Bristol-Myers Squibb · 1 drug in Muscle relaxation, function
Charles University, Czech Republic · 1 drug in Muscle relaxation, function
Eli Lilly · 1 drug in Muscle relaxation, function
Fresenius Kabi · 1 drug in Muscle relaxation, function
Merck & Co. · 1 drug in Muscle relaxation, function
Novartis · 1 drug in Muscle relaxation, function
Pfizer · 1 drug in Muscle relaxation, function

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Muscle relaxation, function:

Cite this brief

Drug Landscape (2026). Muscle relaxation, function — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/muscle-relaxation-function. Accessed 2026-06-10.

Muscle relaxation, function full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing